What is the recommendation for the use of antithrombotic therapy in patients undergoing electrical or pharmacologic cardioversion for AF?
In the context of elective cardioversion, whether electrical or chemical, therapeutic anticoagulation either with adjusted-dose VKAs, or NOACs is currently recommended for a minimum of 3 weeks before, and for a minimum of 4 weeks after, the procedure. In AF of > 48 h duration or unknown duration, a TEE-guided approach provides an alternative strategy to guide anticoagulation management before cardioversion.